Peijia Medical's revenue soars on heart valve and neurovascular product demand

Peijia Medical has reported a strong fiscal year, with revenue growth driven by its heart valve and neurovascular product lines. The company's expansion into new markets and increased hospital partnerships have also boosted performance. Regulatory milestones and upcoming product approvals are now shaping its next phase of development.

The company saw a major rise in transcatheter aortic valve replacement (TAVR) procedures, with implants jumping from 2,008 in 2023 to 4,375 in 2024—a 118% increase. This surge helped push the structural heart disease segment up by 14.4%, reaching around 3,900 implants in the latest fiscal year. Meanwhile, the balloon catheter segment held steady, as higher sales volumes balanced out pricing pressures.

In neurovascular care, demand grew for specialised products like the DCwire micro gold wire and the Syphonet stent retriever. These innovations contributed to the company's overall expansion. Peijia Medical also widened its commercial reach, adding roughly 130 hospitals to its network, now serving over 780 medical facilities.

Regulatory progress played a key role in this growth. The recent approval of the TaurusTrio system by China's National Medical Products Administration (NMPA) opened access to the aortic insufficiency market, creating new revenue opportunities. Looking ahead, the second half of 2026 will be crucial, as decisions on next-generation products—TaurusNXT and GeminiOne—are expected.

For 2025, the company projects revenue between 700 million and 720 million RMB, representing a 14% to 17% year-over-year increase. Final profitability details will be confirmed when audited results are released in March 2026.

Peijia Medical's growth reflects stronger demand for its heart valve and neurovascular treatments, along with an expanded hospital network. The upcoming regulatory decisions on TaurusNXT and GeminiOne will determine whether this momentum continues. Audited financial results in early 2026 will provide further clarity on the company's profitability.